Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Charles Deignan - Chief Financial Officer Conference Call Participants Serge Belanger - Needham & Company Annabel Samimy - Stifel Andreas Argyrides - Wedbush Securities Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by. Welcome to the Clearside Biomedical First Quarter 2023 Finan ...

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ In ...

Novel SCS Microinjector® shows a demonstrated ability for precise delivery into the suprachoroidal space SCS injection procedure commercially accepted by retinal physicians following launch of XIPERE® • Thousands of SCS injections performed Safety profile comparable to intravitreal injections1 • No Serious Adverse Events (SAEs) involving lens injury, suprachoroidal hemorrhage, or endophthalmitis have been observed 6 clinical trials ongoing including partner programs Sources: Clearside data on file | 1Kurup, ...

DOCUMENTS INCORPORATED BY REFERENCE Portions of the Company's definitive proxy statement, to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934, for its 2023 Annual Meeting of Stockholders are incorporated by reference in Part III of the Form 10-K. The risk factors summarized below could materially harm our business, operating results, and/or financial condition, impair our future prospects and/or cause the price of our common stock to decline. These risks are discussed more fully ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Charles Deignan - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham & Company Jonathan Wolleben - JMP Securities Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by and welcome to the Clearside Biomedical Fourth Quarter 2022 Fina ...

LEARSID BIOMEDI Corporate Presentation November 2022 : | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------| | Forward-Looking Statements | | | This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of | 1995, as amended. | Developing and Delivering Treatments that Restore and Preserve Vision for Serious Back of the Eye ...

LEARSID BIOMEDI Corporate Presentation November 2022 : | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------| | Forward-Looking Statements | | | This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of | 1995, as amended. | Developing and Delivering Treatments that Restore and Preserve Vision for Serious Back of the Eye ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2022 Earnings Call Transcript November 9, 2022 8:30 AM ET Company Representatives George Lasezkay - Chief Executive Officer Tom Ciulla - Chief Medical Officer, Chief Development Officer Charles Deignan - Chief Financial Officer Dr. Arshad Khanani - Managing Partner at Sierra Eye Associates, Clinical Associate Professor at the University of Nevada Jenny Kobin - Investor Relations Conference Call Participants Andreas Argyrides - Wedbush Annabel Samimy - Stifel John ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 | --- | --- | --- | |----------------------------------------------------------------------------|--------------------------------------------------|---- ...

LEARSI BIOMEDI Corporate Presentation August 2022 . Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forwardlooking statements conta ...